Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Editas Medicine Inc (EDIT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Editas Medicine's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.35 -0.11    -2.01%
20:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
5.35
0.00
0.00%
21:50:36 - Real-time Data
  • Volume: 1,550,228
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 5.28 - 5.59
Type:  Equity
Market:  United States
Editas Medicine 5.35 -0.11 -2.01%

Editas Medicine Company Profile

 
Read the Editas Medicine Inc company profile to learn more about the business and the management team. View Editas Medicine facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

265

Equity Type

ORD

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Contact Information

Address 11 Hurley Street
Cambridge, 02141
United States
Phone 617 401 9000
Fax -

Top Executives

Name Age Since Title
Emma Reeve 62 2021 Independent Chairman of the Board
Gilmore O’Neill 59 2022 President, CEO & Director
Jessica Hopfield 59 2018 Independent Lead Director
Akshay K. Vaishnaw 61 2016 Independent Director
David T. Scadden 71 2019 Independent Director
Andrew J. Hirsch 53 2017 Independent Director
Bernadette Mary Connaughton 66 2021 Independent Director
Meeta Chatterjee 68 2020 Independent Director
Elliott M. Levy 66 2023 Independent Director
George McDonald Church 70 2013 Co-Founder & Scientific Advisory Board Member
Feng Zhang - 2013 Co-Founder & Scientific Advisory Board Member
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EDIT Price Commentary

Write your thoughts about Editas Medicine Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Florin M Pop
Florin M Pop Mar 02, 2023 7:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long
Winter Hannah-Ward
Winter Hannah-Ward Sep 29, 2021 17:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm long!
Anthony Hall
Anthony Hall Sep 29, 2021 17:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Still long?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email